<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00055926</url>
  </required_header>
  <id_info>
    <org_study_id>CDR0000271533</org_study_id>
    <secondary_id>UCLA-0209105</secondary_id>
    <secondary_id>PFIZER-A4031001</secondary_id>
    <nct_id>NCT00055926</nct_id>
  </id_info>
  <brief_title>CP-724,714 in Treating Patients With Metastatic Breast Cancer</brief_title>
  <official_title>A Phase I Safety and Pharmacokinetic/Pharmacodynamic Study of CP-724, 714 In Patients With Metastatic HER2-Overexpressing Breast Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Jonsson Comprehensive Cancer Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Pfizer</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Jonsson Comprehensive Cancer Center</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      RATIONALE: CP-724,714 may stop the growth of tumor cells by blocking the enzymes necessary&#xD;
      for tumor cell growth.&#xD;
&#xD;
      PURPOSE: Phase I trial to study the effectiveness of CP-724,714 in treating patients who have&#xD;
      metastatic HER2-overexpressing breast cancer.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      OBJECTIVES:&#xD;
&#xD;
        -  Determine the safety and tolerability of CP-724,714 in patients with metastatic&#xD;
           HER2-overexpressing breast cancer.&#xD;
&#xD;
        -  Determine the maximum tolerated dose of this drug in these patients.&#xD;
&#xD;
        -  Determine, preliminarily, any antitumor activity of this drug in these patients.&#xD;
&#xD;
        -  Determine the pharmacokinetics of this drug in these patients.&#xD;
&#xD;
        -  Determine the relationship of drug-related adverse events to pharmacokinetic exposure&#xD;
           parameters in these patients.&#xD;
&#xD;
        -  Determine the relationship of changes in serum HER2 extracellular domain and HER2&#xD;
           receptor tyrosine kinase phosphorylation to pharmacokinetic exposure parameters and&#xD;
           clinical outcome in patients treated with this drug.&#xD;
&#xD;
      OUTLINE: This is an open-label, dose-escalation, multicenter study.&#xD;
&#xD;
      Patients receive oral CP-724,714 on days 1 and 3-21 during course 1 and then daily during&#xD;
      subsequent courses. Courses repeat every 3 weeks for up to 1 year in the absence of disease&#xD;
      progression or unacceptable toxicity.&#xD;
&#xD;
      Cohorts of 3-6 patients receive escalating doses of CP-724,714 until the maximum tolerated&#xD;
      dose (MTD) is determined. The MTD is defined as the dose preceding that at which 2 of 3 or 2&#xD;
      of 6 patients experience dose-limiting toxicity.&#xD;
&#xD;
      Patients are followed for at least 30 days.&#xD;
&#xD;
      PROJECTED ACCRUAL: A total of 3-20 patients will be accrued for this study within 6 months.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>January 2003</start_date>
  <completion_date type="Actual">May 2005</completion_date>
  <primary_completion_date type="Actual">December 2004</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <enrollment type="Actual">9</enrollment>
  <condition>Breast Cancer</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>CP-724,714</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Histologically or cytologically confirmed HER2-overexpressing breast cancer&#xD;
&#xD;
          -  Prior or newly documented HER2 amplification by fluorescence in situ hybridization&#xD;
             (FISH)&#xD;
&#xD;
          -  Progressive metastatic disease&#xD;
&#xD;
          -  Must have received at least one prior chemotherapy regimen for metastatic breast&#xD;
             cancer&#xD;
&#xD;
          -  At least 1 measurable or evaluable lesion&#xD;
&#xD;
          -  At least 1 lesion accessible for 2 separate core biopsies for pharmacodynamic&#xD;
             evaluation&#xD;
&#xD;
          -  18 and over&#xD;
&#xD;
          -  Male or female&#xD;
&#xD;
          -  ECOG 0-1&#xD;
&#xD;
          -  Life expectancy, More than 3 months&#xD;
&#xD;
          -  Hematopoietic&#xD;
&#xD;
               -  Absolute neutrophil count at least 1,500/mm^3*&#xD;
&#xD;
               -  Platelet count at least 100,000/mm^3* NOTE: *Without hematopoietic growth factors&#xD;
                  or transfusions&#xD;
&#xD;
          -  Hepatic&#xD;
&#xD;
               -  Bilirubin no greater than 1.5 mg/dL&#xD;
&#xD;
               -  AST/ALT no greater than 2.5 times upper limit of normal (ULN) (5 times ULN if&#xD;
                  liver metastases are present)&#xD;
&#xD;
          -  Renal&#xD;
&#xD;
               -  Creatinine no greater than 1.5 times ULN OR&#xD;
&#xD;
               -  Creatinine clearance at least 60 mL/min&#xD;
&#xD;
          -  Cardiovascular&#xD;
&#xD;
               -  12-lead ECG with normal tracing&#xD;
&#xD;
          -  history of cardiovascular disease (i.e., ischemic heart disease, arrhythmia, or&#xD;
             congestive heart failure) unless asymptomatic for the past year with no requirement&#xD;
             for antiarrhythmics or a clinically significant medical management change&#xD;
&#xD;
          -  Gastrointestinal&#xD;
&#xD;
               -  Able to take oral medication* Negative pregnancy test&#xD;
&#xD;
               -  Fertile patients must use effective contraception&#xD;
&#xD;
          -  At least 4 weeks since prior trastuzumab (Herceptin)&#xD;
&#xD;
          -  At least 4 weeks since other prior biologic therapy or immunotherapy&#xD;
&#xD;
          -  At least 4 weeks since prior chemotherapy (6 weeks for mitomycin or nitrosoureas)&#xD;
&#xD;
          -  At least 6 months since prior doxorubicin or doxorubicin equivalents without any prior&#xD;
             or developing signs or symptoms of cardiomyopathy&#xD;
&#xD;
          -  No cumulative doses of more than 300 mg/m^2&#xD;
&#xD;
          -  At least 2 weeks since prior hormonal therapy for the primary disease&#xD;
&#xD;
          -  Concurrent hormone replacement therapy or luteinizing hormone-releasing hormone&#xD;
             agonists allowed&#xD;
&#xD;
          -  At least 4 weeks since prior radiotherapy&#xD;
&#xD;
          -  At least 3 weeks since prior major surgery (2 weeks for minor surgery)&#xD;
&#xD;
          -  Recovered from prior therapy&#xD;
&#xD;
          -  At least 4 weeks since prior investigational treatment&#xD;
&#xD;
          -  Coumarin or heparin derivatives allowed for the prevention of deep vein thrombosis or&#xD;
             port patency&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  known or clinically suspected brain metastases or leptomeningeal disease&#xD;
&#xD;
          -  symptomatic edema or third-space fluid (e.g., ascites or pleural effusions)&#xD;
&#xD;
          -  known hepatitis B or C infection&#xD;
&#xD;
          -  significant ECG changes that require medical intervention&#xD;
&#xD;
          -  QTc interval less than 460 msec&#xD;
&#xD;
          -  No history of torsade or other symptomatic QTc abnormality&#xD;
&#xD;
          -  LVEF greater than 50% by MUGA&#xD;
&#xD;
          -  gastrointestinal abnormality that would require medications (including all antacids)&#xD;
&#xD;
          -  persistent symptoms of an esophageal or digestive disorder&#xD;
&#xD;
          -  pregnant or nursing&#xD;
&#xD;
          -  known HIV infection&#xD;
&#xD;
          -  active infection&#xD;
&#xD;
          -  concurrent uncontrolled systemic disorders or laboratory abnormalities that would&#xD;
             preclude study drug safety evaluation&#xD;
&#xD;
          -  mental disorder that would preclude study compliance or ability to give informed&#xD;
             consent&#xD;
&#xD;
          -  No more than 2 prior trastuzumab-based regimens for advanced disease&#xD;
&#xD;
          -  concurrent immunotherapy&#xD;
&#xD;
          -  more than 1 prior anthracycline- or anthracenedione-containing regimen (except with&#xD;
             approval of the sponsor)&#xD;
&#xD;
          -  prior high-dose chemotherapy with hematopoietic stem cell transplantation&#xD;
&#xD;
          -  concurrent anticancer chemotherapy&#xD;
&#xD;
          -  No concurrent anticancer hormonal therapy, including tamoxifen&#xD;
&#xD;
          -  prior radiotherapy to the only disease site that would be assessed for response&#xD;
&#xD;
          -  concurrent radiotherapy&#xD;
&#xD;
          -  prior partial or complete gastrectomy&#xD;
&#xD;
          -  concurrent antiarrhythmics&#xD;
&#xD;
          -  concurrent antacids&#xD;
&#xD;
          -  concurrent anticoagulant at therapeutic doses&#xD;
&#xD;
          -  other concurrent experimental anticancer medications for breast cancer&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Carolyn Britten, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Jonsson Comprehensive Cancer Center</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Jonsson Comprehensive Cancer Center, UCLA</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90095-1781</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>August 2012</verification_date>
  <study_first_submitted>March 6, 2003</study_first_submitted>
  <study_first_submitted_qc>March 6, 2003</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 7, 2003</study_first_posted>
  <last_update_submitted>July 30, 2020</last_update_submitted>
  <last_update_submitted_qc>July 30, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">August 3, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>recurrent breast cancer</keyword>
  <keyword>stage IV breast cancer</keyword>
  <keyword>male breast cancer</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Breast Neoplasms</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

